Abstracts tagged "Outcome measures"

Abstract Number: 2837 • 2013 ACR/ARHP Annual Meeting
Higher Disease Activity Leads To More Damage In The Early Phases Of Ankylosing Spondylitis: 12-Year Data From The OASIS Cohort
Sofia Ramiro¹, A.M. van Tubergen², Désirée van der Heijde³, Carmen Stolwijk⁴, Maxime Dougados⁵, Filip Van den Bosch⁶ and Robert Landewé⁷, ¹Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands
Background/Purpose: For years, it was unclear if inflammation and radiographic progression were related in ankylosing spondylitis (AS), but studies were only of short follow-up and…
Abstract Number: 1662 • 2013 ACR/ARHP Annual Meeting
Developing Guideline For Polymyalgia Rheumatica: Prioritisation Of Outcome Measures – Perspective Of Patients, General Practitioners and Rheumatologists
Yogesh Singh¹, Christian Dejaco^2,3, Sarah Mackie⁴, Daniel Ching⁵, Artur Bachta⁶, Ajesh Maharaj⁷, Alexandre Wagner⁸, Manuela Lima⁹, David Jayne¹⁰, Kevin Barraclough¹¹, Christian D Mallen¹², Stephen P. Merry¹³, Jane Hollywood¹⁴, Madeline Whitlock¹⁵, Kate Gilbert¹⁶, Pamela Hildreth¹⁶, Jennifer Nott¹⁶, Hannah Padbury¹⁶, Jean Miller¹⁶, Lorna Neill¹⁶, David Tronnier¹⁷, Pablo Perel¹⁸, Andrew Hutchings¹⁹, Dario Camellino²⁰, Steven E. Carsons²¹, William Docken²², Christina Duftner²³, Andy Abril²⁴, Robert F. Spiera²⁵, Colin T. Pease²⁶, Andreas P. Diamantopoulos²⁷, Frank Buttgereit²⁸, Peter V. Balint²⁹, Elisabeth Nordborg³⁰, Lina Bianconi³¹, Billy Fashanu¹⁵, Shunsuke Mori³², Víctor M. Martínez-Taboada³³, Maria C. Cid³⁴, Wolfgang A. Schmidt³⁵, Marco A. Cimmino³⁶, Michael Schirmer³⁷, Carlo Salvarani³⁸, Eric L. Matteson³⁹ and Bhaskar Dasgupta⁴⁰, ¹Rheumatology, Southend university hospital, Westcliff-on-sea, United Kingdom, ²Rheumatology and Immunology, Medical University Graz, Graz, Austria, ³Department of Rheumatology and Immunology, Medical University Graz, Graz A-8036, Austria, ⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ⁵Timaru Hospital, Timaru, New Zealand, ⁶Military Medical Institute, Warsaw, Poland, ⁷Prince Mshiyeni Memorial Hospital, Durban, South Africa, ⁸Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁹Universidade dos Açores, Azores, Portugal, ¹⁰Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ¹¹Hoyland House General Practice, Painswick, United Kingdom, ¹²Arthritis Research UK Primary Care Centre, University of Keele, Keele, United Kingdom, ¹³Family Medicine, Mayo Clinic, Rochester, MN, ¹⁴Rheumatology, Southend Hospital, Southend, United Kingdom, ¹⁵Southend University Hospital, Southend, United Kingdom, ¹⁶PMRGCAUK, Southend, United Kingdom, ¹⁷patients' representative, Rochester, MN, ¹⁸London School of Hygiene & Tropical Medicine, London, United Kingdom, ¹⁹Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom, ²⁰Dipartimento Medicina Interna, Clinica Reumatologica, Genova, Italy, ²¹Div of Rheumatology, Winthrop University Hospital, Mineola, NY, ²²Brigham Orth & Arthritis Center, Chestnut Hill, MA, ²³Internal Medicine, Hopital Kufstein, Kufstein, Austria, ²⁴Rheumatology, Mayo Clinic Florida, Jacksonville, FL, ²⁵Rheumatology, Hospital for Special Surgery, New York, NY, ²⁶Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²⁷Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²⁸Charité - Universitätsmedizin Berlin, Berlin, Germany, ²⁹Rheumatology, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ³⁰Sahlgenska University Hospital, Goteborg, Sweden, ³¹Ambulatorio Medicina Generale, Bibbiano, Italy, ³²Clinical Research Center for Rheumatic Diseases, NHO Kumamoto Saishunsou National Hospital, Kumamoto, Japan, ³³Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV., Santander, Spain, ³⁴Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ³⁵Med Ctr Rheumatology Berlin Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ³⁶Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ³⁷Internal medicine, Innsbruck Medical University, Innsbruck, Austria, ³⁸Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ³⁹Rheumatology, Mayo Clinic, Rochester, MN, ⁴⁰Southend University Hospital, Essex, United Kingdom
Background/Purpose: To explore similarities and differences between rheumatologists (rheum), general practitioners (GP) and patients (pt) regarding the relevance of outcome parameters in polymyalgia rheumatica (PMR).Methods:…
Abstract Number: 2852 • 2013 ACR/ARHP Annual Meeting
Real-Life Assessment Of The Validity Of Patient Global Impression Of Change In Fibromyalgia
John S. Sampalis^1,2, Mary-Ann Fitzcharles³, Peter A. Ste-Marie⁴, Emmanouil Rampakakis^1,2 and Yoram Shir⁴, ¹JSS Medical Research, Montreal, QC, Canada, ²Jewish General Hospital, McGill University, Montreal, QC, Canada, ³Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ⁴Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Assessing fibromyalgia (FM) is challenging due to the lack of hard outcomes and the need to rely on patient-reported symptoms. Completion of questionnaires by…
Abstract Number: 1624 • 2013 ACR/ARHP Annual Meeting
Lupus Risk Alleles With High Ethnic Variability Worldwide Are Associated With Renal Disease In Hispanic Patients
Belinda Waltman¹, Kimberly E. Taylor², Joanne Nititham³ and Lindsey A. Criswell³, ¹Department of Medicine, University of California, San Francisco, San Francisco, CA, ²Department of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ³Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionately affects minority patients. Non-European ancestry is associated with more severe disease, and conversely, European ancestry is associated with a…
Abstract Number: 2792 • 2013 ACR/ARHP Annual Meeting
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Performance Improvement On Juvenile Idiopathic Arthritis Quality Measures
Julia G. Harris^1,2, Esi Morgan DeWitt³, Ronald M. Laxer^4,5, Stacy P. Ardoin⁶, Beth S. Gottlieb⁷, Judyann C. Olson^1,2, Murray H. Passo⁸, Jennifer E. Weiss⁹, Daniel J. Lovell¹⁰, Tzielan C. Lee¹¹, Sheetal S. Vora^12,13, Nancy Griffin¹⁴, Jason A. Stock¹⁵, Lynn M. Darbie¹⁴ and Catherine A. Bingham¹⁶, ¹Medical College of Wisconsin, Milwaukee, WI, ²Children's Hospital of Wisconsin, Milwaukee, WI, ³Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁶Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, ⁷Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁸Pediatrics, Medical University of South Carolina, Charleston, SC, ⁹Pediatric Rheumatology, Hackensack University Medical Center, Hackensack, NJ, ¹⁰Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹¹Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ¹²University of North Carolina Chapel Hill, Chapel Hill, NC, ¹³Levine Children's Hospital and Carolinas Medical Center, Charlotte, NC, ¹⁴James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁵Biostatistics & Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁶Pediatric Rheumatology, Penn State Hershey Children's Hospital, Hershey, PA
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a multi-site learning network designed to improve outcomes of juvenile idiopathic arthritis (JIA) care. Teams…
Abstract Number: 1554 • 2013 ACR/ARHP Annual Meeting
Real-World Effectiveness Of Infliximab In The Treatment Of Psoriatic Arthritis Over 12 Months: The Canadian Experience
Proton Rahman¹, Majed M. Khraishi², William Bensen³, John T. Kelsall⁴, Brian D. Hanna⁵, Craig Watts⁶, Emmanouil Rampakakis⁷, John S. Sampalis⁷, May Shawi⁸, Susan M. Otawa⁹ and Allen J. Lehman⁹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Nexus Clinical Research, St John's, NF, Canada, ³St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁵Rheumatology, McMaster University, Ontario, Kitchener, ON, Canada, ⁶Department of Rheumatology, McGill University and Montreal General Hospital, Sainte-Anne-de-Bellevue, QC, Canada, ⁷JSS Medical Research, Montreal, QC, Canada, ⁸Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) has been demonstrated in numerous controlled clinical trials. Longitudinal observational studies assessing the…
Abstract Number: 2641 • 2013 ACR/ARHP Annual Meeting
Earlier Admission To Specialized Care, Intensified Treatment and Improved Outcome In Patients With Autoimmune Connective Tissue Disorders and Vasculitides In Germany 2011 Compared To 1995
Dörte Huscher¹, Katinka Albrecht², Katja Thiele², Sascha Bischoff², Jutta G. Richter³, Ina Kötter⁴, Wolfgang Ochs⁵ and Angela Zink¹, ¹German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁴ZIRS, Centre for Interdisciplinary Rheumatology Stuttgart, Stuttgart, Germany, ⁵Rheumatologist in private practice, Bayreuth, Germany
Background/Purpose: Compared to rheumatoid arthritis and other arthritis-associated rheumatic diseases, autoimmune connective tissue disorders and vasculitides are still in the early stages of biological therapies.…
Abstract Number: 1342 • 2013 ACR/ARHP Annual Meeting
Prognosis In Espoir Rheumatoid Arthritis Cohort At 24 Months According To Remission Status At 12 Months: No Differences In Radiographic Scores According To Prior Remission Status, But Significant Differences In HAQ Scores, Highest For Boolean and RAPID3RJ1 Criteria
Isabel Castrejón¹, Maxime Dougados², Bernard Combe³, Francis Guillemin⁴, Bruno Fautrel⁵ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Cochin Hospital, Paris, France, ³CHU Lapeyronie, Montpellier, France, ⁴Hopitaux de Brabois, Nancy, France, ⁵APHP, Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Different criteria for remission in rheumatoid arthritis (RA) have been developed from a Core Data Set of 7 measures for the DAS28, SDAI, CDAI…
Abstract Number: 2536 • 2013 ACR/ARHP Annual Meeting
Lupus Impact Tracker Is Responsive To Changes In Physician Assessed Disease Status By Systemic Lupus Erythematosus Responder Index
Hervé Devilliers^1,2, Mark Kosinski³, Cindy Garris⁴ and Meenakshi Jolly⁵, ¹Clinical investigation and clinical epidemiology center (INSERM CIE01), Dijon, France, ²Internal medicine and systemic disease unit, Dijon University Hospital, Dijon, France, ³QualityMetric Inc, Lincoln, RI, ⁴US Health Outcomes, GlaxoSmithKline R&D, Research Triangle Park, NC, ⁵Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Lupus Impact Tracker (LIT) is a 10-item patient reported outcome tool to measure the impact of Systemic Lupus Erythematosus (SLE) or its treatment on…
Abstract Number: 1351 • 2013 ACR/ARHP Annual Meeting
A Comparison Of The Clinical Effectiveness Of Treatment Strategies For Active RA Patients : Using a Prospective Biologic Registry (BIOPSY) and an RA Specific Cohort (KORONA)
Yoon-Kyoung Sung^1,2, Soo-Kyung Cho^1,2, Chan-Bum Choi^3,4, Soyoung Won⁵, So-Young Bang⁶, Hoon-Suk Cha⁷, Jung-Yoon Choe⁸, Won Tae Chung⁹, Seung-Jae Hong¹⁰, Jae-Bum Jun⁴, Hyoun Ah Kim¹¹, Jinseok Kim¹², Seong-Kyu Kim⁸, Tae-Hwan Kim⁴, Hye-Soon Lee¹³, Jaejoon Lee⁷, Jisoo Lee¹⁴, Shin-Seok Lee¹⁵, Sung Won Lee¹⁶, Yeon-Ah Lee¹⁰, Seong-Su Nah¹⁷, Chang-Hee Suh¹⁸, Dae-Hyun Yoo⁴, Bo Young Yoon¹⁹ and Sang-Cheol Bae^1,2, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Department of Rheumatology, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁵Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁶Hanyang University Guri Hospital, Guri, South Korea, ⁷Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁸Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, ¹⁰Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ¹¹Ajou University Hospital, Suwon, South Korea, ¹²Division of Rheumatology, Internal Medicine, Jeju National University Hospital, Jeju, Korea, South Korea, ¹³Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ¹⁴Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, ¹⁵Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ¹⁶Rheumatology, Dong-A University Hospital, Busan, South Korea, ¹⁷Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, South Korea, ¹⁸Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, ¹⁹Inje University Ilsan Paik Hospital, Goyang, South Korea
Background/Purpose: The results from RCTs may not be generalizable to clinical practice because of their inclusion and exclusion criteria. Instead, observational cohorts and registries might…
Abstract Number: 2292 • 2013 ACR/ARHP Annual Meeting
Factors Affecting The Discrepancy Between Physician and Patient Global Assessment Of Disease Activity In Early and Established Rheumatoid Arthritis Patients- Results From The Ontario Best Practices Initiative
Pooneh Akhavan¹, Binu Jacob², Edward C. Keystone^3,4, Xiuying Li⁵, J. Carter Thorne⁶ and Claire Bombardier⁷, ¹Medicine, Early Rheumatoid Arthritis Program, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ³Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, Canada, ⁴University of Toronto/Mount Sinai Hospital, Toronto, ON, Canada, ⁵Clinical Decision Making and Health Care, University Health Network, Toronto, ON, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Discrepancy between patient (PGA) and physician (MDGA) global assessments in Rheumatoid Arthritis (RA) can adversely affect therapeutic decisions. The pattern of PGA and MDGA,…
Abstract Number: 1264 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Quality Indicators and Disease Damage In Childhood-Onset Systemic Lupus Erythematosus Patients
Julia G. Harris^1,2, Kristyn I. Maletta³, Evelyn M. Kuhn³ and Judyann C. Olson^1,2, ¹Medical College of Wisconsin, Milwaukee, WI, ²Children's Hospital of Wisconsin, Milwaukee, WI, ³National Outcomes Center, Children's Hospital of Wisconsin, Milwaukee, WI
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect virtually every organ system and may lead to significant morbidities. A…
Abstract Number: 2300 • 2013 ACR/ARHP Annual Meeting
Rheumatologists Who Are Consistently Using An Objective Outcome Instrument Do Not “Treat To Target” In a Real World Setting
Gary Craig^1,2, Howard Kenney^1,2, Keith Knapp² and Sergio Schwartzman³, ¹Arthritis Northwest PLLC., Spokane, WA, ²T3 JointMan LLC., Spokane, WA, ³Rheumatology, Hosp for Special Surgery, New York, NY
Background/Purpose: The public database JointManTMwas launched January 2012 with a mission to provide a practical outcome tool to manage patients with RA in a clinical…
Abstract Number: 968 • 2013 ACR/ARHP Annual Meeting
Success Of Educational Intervention In Improving The Management Of Rheumatoid Arthritis
Nimish Mehta and Ronald Viggiani, Medscape, LLC, New York, NY
Background/Purpose: In many patients with rheumatoid arthritis (RA), the disease is not adequately controlled and only a minority of patients attain the goal of consistent…
Abstract Number: 2238 • 2013 ACR/ARHP Annual Meeting
Comparison Of The Long-Term Outcome For Rheumatoid Arthritis Patients With persistent Moderate Disease Activity Or Disease Remission During The First Year After Diagnosis: Data From The Espoir Cohort
Bernard Combe¹, Isabelle Logeart², M. Belkacemi³, S Dadoun⁴, Jean-Pierre Daurès⁵ and Maxime Dougados⁶, ¹Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France, ²Pfizer, Paris, France, ³CHRU Montpellier, Montpellier, France, ⁴Paris-Pitié Salpêtrière University Hospital, Paris, France, ⁵Service BESPIM, CHU, Nimes, France, ⁶Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France
Background/Purpose: The Treat to Target and EULAR recommendations highlighted the need for achieving and maintaining remission in patients with early RA. We investigated if early…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].